Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fewer Device Submissions Sought In Subcommittee-Passed 'Cures' Bill

This article was originally published in The Gray Sheet

Executive Summary

The House Energy & Commerce Health Subcommittee moved the 21st Century Cures bill forward in a May 14 mark. The legislation includes a newly fleshed-out measure allowing third-party quality systems certifications to replace certain PMA supplements, and another focused on exempting more devices from 510(k)s.

You may also be interested in...



House Set To Vote On Cures Nov. 30; Latest Version Includes 510(k)s In Breakthrough Pathway

A combined House/Senate "21st Century Cures" package will get a vote in the House on Nov. 30, and soon in the Senate. The medical innovation package includes a breakthrough device pathway that, in its current form, would allow 510(k), as well as PMA and de novo, devices to participate. The bill also provides a modest $500m to help support a range of additional FDA device and drug pathway streamlining reforms. Meanwhile, it would authorize $4.8bn for the Precision Medicine Initiative, a BRAIN Initiative, and for cancer "Moonshot" research funds at NIH.

Human Factors Questions Drive Rise In FDA Inter-Center Consults

Formal consultations between FDA's product centers are becoming more frequent, and they are often triggered by questions about human factors issues, says Office of Combination Products Director Thinh Nguyen.

Shortened ‘Cures’ Draft Retains Breakthrough Pathway, Device Reforms

But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.

Related Content

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel